Estrace (estradiol)
/ AbbVie
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
106
Go to page
1
2
3
4
5
December 05, 2025
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer
(clinicaltrials.gov)
- P2 | N=5 | Active, not recruiting | Sponsor: Mayo Clinic | Trial completion date: Jul 2026 ➔ Dec 2026
Trial completion date • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • PD-L1 • PGR
October 30, 2025
Hormonal Status on Blood Flow and Tissue in Pelvic Organ Prolapse
(clinicaltrials.gov)
- P4 | N=7 | Terminated | Sponsor: The University of Texas Medical Branch, Galveston | N=10 ➔ 7
Enrollment change • Women's Health
October 14, 2025
Trends in Prescription Cost Savings for Vaginal Estrogen.
(PubMed, Urogynecology (Phila))
- "While significant price variations for prescriptions were seen on a regional level within zip codes and between pharmacies, notable price savings were consistently seen with CPD and GoodRx, offering a solution to the financial strain that these prescriptions may impose."
HEOR • Journal • Women's Health
March 12, 2025
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
(clinicaltrials.gov)
- P2 | N=60 | Recruiting | Sponsor: University of Washington | Trial completion date: Jun 2026 ➔ Jun 2028 | Trial primary completion date: Mar 2025 ➔ Mar 2027
Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor
January 31, 2025
Estrogen and Fear in PTSD
(clinicaltrials.gov)
- P3 | N=64 | Completed | Sponsor: The University of Texas Health Science Center, Houston | Recruiting ➔ Completed | Trial completion date: Jul 2025 ➔ Dec 2024 | Trial primary completion date: Jul 2025 ➔ May 2024
Trial completion • Trial completion date • Trial primary completion date • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder
January 16, 2025
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
(clinicaltrials.gov)
- P2 | N=60 | Recruiting | Sponsor: University of Washington | Suspended ➔ Recruiting
Enrollment open • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor
November 21, 2024
Estradiol Plus Olaparib for Breast Cancer (PHOEBE)
(clinicaltrials.gov)
- P1 | N=6 | Recruiting | Sponsor: Mary D Chamberlin | Not yet recruiting ➔ Recruiting
Enrollment open • Metastases • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2
November 29, 2024
VITAL-E: Silicone Gel Vs. Estrogen Vaginal Cream for the Management of Genitourinary Syndrome of Menopause
(clinicaltrials.gov)
- P=N/A | N=100 | Recruiting | Sponsor: Stratpharma AG | Trial completion date: Jun 2024 ➔ Nov 2025 | Trial primary completion date: Jun 2024 ➔ Nov 2025
Head-to-Head • Trial completion date • Trial primary completion date • Women's Health
September 20, 2024
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
(clinicaltrials.gov)
- P2 | N=60 | Suspended | Sponsor: University of Washington | Recruiting ➔ Suspended
Metastases • Trial suspension • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor
August 19, 2024
Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome
(clinicaltrials.gov)
- P4 | N=152 | Recruiting | Sponsor: Walter Reed National Military Medical Center | Trial completion date: Jan 2024 ➔ Jan 2027 | Trial primary completion date: Dec 2023 ➔ Dec 2026
Trial completion date • Trial primary completion date • Overactive Bladder
August 19, 2024
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer
(clinicaltrials.gov)
- P2 | N=5 | Active, not recruiting | Sponsor: Mayo Clinic | Enrolling by invitation ➔ Active, not recruiting | N=38 ➔ 5
Enrollment change • Enrollment closed • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • PD-L1 • PGR
August 15, 2024
Estrogen and Fear in PTSD
(clinicaltrials.gov)
- P3 | N=80 | Recruiting | Sponsor: NYU Langone Health | Trial completion date: Jul 2024 ➔ Jul 2025 | Trial primary completion date: Jul 2024 ➔ Jul 2025
Trial completion date • Trial primary completion date • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder
July 11, 2024
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
(clinicaltrials.gov)
- P2 | N=60 | Recruiting | Sponsor: University of Washington | Not yet recruiting ➔ Recruiting
Enrollment open • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor
June 03, 2024
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer
(clinicaltrials.gov)
- P2 | N=38 | Enrolling by invitation | Sponsor: Mayo Clinic | Trial completion date: Apr 2024 ➔ Jul 2026 | Trial primary completion date: Apr 2024 ➔ Jul 2026
Metastases • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • PD-L1 • PGR
May 16, 2024
Locally administered nanosuspension increases delivery of estradiol for the treatment of vaginal atrophy in mice.
(PubMed, Drug Deliv Transl Res)
- "Further, we demonstrate compatibility of the estradiol NS with vaginal bacteria in vitro. We demonstrate that a Pluronic F127-coated estradiol NS may be a viable option for the treatment of post-menopausal vaginal atrophy."
Journal • Preclinical • Vaginal Atrophy • Women's Health
April 09, 2024
Adherence to Vaginal Estrogen Therapy in Hypoestrogenic Women With Recurrent Urinary Tract Infections
(clinicaltrials.gov)
- P4 | N=111 | Recruiting | Sponsor: University of California, Irvine
Adherence • New P4 trial • Infectious Disease • Nephrology
March 26, 2024
Vaginal Estrogen Prescribing and Cost Trends Among Medicare Part D Beneficiaries.
(PubMed, Urogynecology (Phila))
- "Vaginal estrogen claims, beneficiaries, and total expenditures across all provider types have decreased from 2016 to 2020. However, spending per beneficiary and VE claims have increased. Our data suggest that utilization and accessibility of vaginal estrogen may be influenced, in part, by cost."
Journal • Medicare • Reimbursement • US reimbursement • Breast Cancer • Obstetrics • Oncology • Solid Tumor
March 19, 2024
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
(clinicaltrials.gov)
- P2 | N=60 | Not yet recruiting | Sponsor: University of Washington | Trial completion date: Mar 2025 ➔ Jun 2026
Metastases • Trial completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor
March 15, 2024
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer
(clinicaltrials.gov)
- P2 | N=38 | Enrolling by invitation | Sponsor: Mayo Clinic | Recruiting ➔ Enrolling by invitation
Enrollment status • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • PD-L1 • PGR
March 13, 2024
Estradiol Plus Olaparib for Breast Cancer (PHOEBE)
(clinicaltrials.gov)
- P1 | N=6 | Not yet recruiting | Sponsor: Mary D Chamberlin | Initiation date: Feb 2024 ➔ May 2024
Metastases • Trial initiation date • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2
March 12, 2024
Hormonal Status on Blood Flow and Tissue in Pelvic Organ Prolapse
(clinicaltrials.gov)
- P4 | N=10 | Terminated | Sponsor: The University of Texas Medical Branch, Galveston | Trial completion date: Dec 2024 ➔ Dec 2023 | Active, not recruiting ➔ Terminated | Trial primary completion date: May 2024 ➔ Dec 2023; Collaborator moved and not able to recreate full study team
Trial completion date • Trial primary completion date • Trial termination • Women's Health
January 11, 2024
Topical Vaginal Estrogen for Postpartum Obstetric Anal Sphincter Injury Recovery
(clinicaltrials.gov)
- P4 | N=50 | Recruiting | Sponsor: University of Alabama at Birmingham | Trial completion date: Jul 2024 ➔ Jul 2026 | Trial primary completion date: Jan 2024 ➔ Jan 2026
Trial completion date • Trial primary completion date • Obstetrics • Sexual Disorders • Urinary Incontinence • Urology
December 21, 2023
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
(clinicaltrials.gov)
- P2 | N=60 | Not yet recruiting | Sponsor: University of Washington
Metastases • New P2 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor
January 01, 2024
STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)
(clinicaltrials.gov)
- P2 | N=36 | Recruiting | Sponsor: Dartmouth-Hitchcock Medical Center
Metastases • Trial completion date • Trial primary completion date • Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER
January 01, 2024
Estradiol Plus Olaparib for Breast Cancer (PHOEBE)
(clinicaltrials.gov)
- P1 | N=6 | Not yet recruiting | Sponsor: Dickinson
Metastases • Trial completion date • Trial initiation date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2
1 to 25
Of
106
Go to page
1
2
3
4
5